Search Menu
Photonics Media Photonics Marketplace Photonics Spectra BioPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook

BioLight, 2 Asian Firms Invest $7.2M in Glaucoma Treatment Tech Company IOPtima

Facebook Twitter LinkedIn Email
BioLight Life Sciences Investments Ltd. and two Asia-based venture capital firms will provide $7.2 million in funding to BioLight subsidiary IOPtima Ltd.

Financing will support commercialization and regulatory approval of the IOPtimate system — a minimally invasive surgical ophthalmic device — in the U.S. The CO2 laser-based technology enables the performance of a filtration surgery to treat glaucoma without penetrating the inner part of the eyeball. The procedure provides high efficacy, and allows for reductions in postoperative complications and use of eye drops, according to BioLight.

The system has been sold in Hong Kong, Poland, Hungary, Romania and Peru; distribution agreements are under negotiation in additional countries.

The two venture firms and BioLight will invest $6 million and $1.2 million, respectively, on the basis of a $13.5 million premoney valuation of IOPtima. BioLight will hold approximately 71 percent of IOPtima's issued and outstanding shares. The private placement is expected to close within the next few weeks, subject to standard closing terms.

For more information, visit

Jan 2016
The branch of medicine involved in the study of the anatomy, functions, diseases and treatments of the eye.

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2023 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, [email protected]

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.